Tokyo Tape
Sign in
← GNI Group

Quarterly report · Q3

2160.TEDINET S100PN1P
Period2022-01-01 → 2022-09-30
Filed2022-11-14
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 62
MetricValuePeriodScopeSource row
Revenue¥12.8bn2022-01-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥4.6bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Revenue¥12.7bn2021-01-01 → 2021-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥9.5bn2021-01-01 → 2021-09-30Cons.Revenue IFRS
Revenue¥3.1bn2021-07-01 → 2021-09-30dCons.Revenue IFRS
Operating income¥1.5bn2022-01-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥490m2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Operating income¥2.0bn2021-01-01 → 2021-09-30Cons.Operating profit loss IFRS
Operating income¥505m2021-07-01 → 2021-09-30dCons.Operating profit loss IFRS
Profit before tax¥1.2bn2022-01-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥433m2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Profit before tax¥1.1bn2021-01-01 → 2021-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥1.6bn2021-01-01 → 2021-09-30Cons.Profit loss before tax IFRS
Profit before tax¥371m2021-07-01 → 2021-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥1.1bn2022-01-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥400m2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥1.1bn2021-01-01 → 2021-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥1.3bn2021-01-01 → 2021-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥353m2021-07-01 → 2021-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥324m2022-01-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥126m2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Net income¥55m2021-01-01 → 2021-12-31Cons.Profit loss IFRS (5-year summary)
Net income¥875m2021-01-01 → 2021-09-30Cons.Profit loss IFRS
Net income¥130m2021-07-01 → 2021-09-30dCons.Profit loss IFRS
Total assets¥36.5bnat 2022-09-30Cons.Assets IFRS
Total assets¥30.3bnat 2021-12-31Cons.Assets IFRS
Total assets¥29.8bnat 2021-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥14.4bnat 2022-09-30Cons.Liabilities IFRS
Total liabilities¥11.0bnat 2021-12-31Cons.Liabilities IFRS
Net assets / equity¥22.0bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥19.3bnat 2021-12-31Cons.Equity IFRS
Net assets / equity¥19.4bnat 2021-09-30Cons.Equity IFRS
Net assets / equity¥12.8bnat 2020-12-31dCons.Equity IFRS
Equity (owners)¥22.9bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥18.9bnat 2021-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥18.5bnat 2021-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥12.7bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥14.4bnat 2021-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥13.9bnat 2021-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥10.3bnat 2020-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow−¥163m2022-01-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥552m2021-01-01 → 2021-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥755m2021-01-01 → 2021-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥2.9bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥261m2021-01-01 → 2021-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥884m2021-01-01 → 2021-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥299m2022-01-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥2.9bn2021-01-01 → 2021-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥3.2bn2021-01-01 → 2021-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥22.672022-01-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥8.422022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥22.722021-01-01 → 2021-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥27.692021-01-01 → 2021-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥7.442021-07-01 → 2021-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥22.462022-01-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥8.282022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥22.082021-01-01 → 2021-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥26.872021-01-01 → 2021-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥7.322021-07-01 → 2021-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio62.8%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio62.3%at 2021-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio62.1%at 2021-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-01-01 → 2022-09-30−¥38m
Reconciling Itemsreconcilingrevenue intersegment2022-01-01 → 2022-09-30−¥38m
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue2022-01-01 → 2022-09-30¥1.8bn
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue external2022-01-01 → 2022-09-30¥1.7bn
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue intersegment2022-01-01 → 2022-09-30¥38m
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentsegment profit2022-01-01 → 2022-09-30¥699m
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentrevenue2022-01-01 → 2022-09-30¥11.0bn
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentrevenue external2022-01-01 → 2022-09-30¥11.0bn
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentsegment profit2022-01-01 → 2022-09-30¥796m
—segment totalrevenue2022-01-01 → 2022-09-30¥12.8bn
—segment totalrevenue external2022-01-01 → 2022-09-30¥12.8bn
—segment totalrevenue intersegment2022-01-01 → 2022-09-30¥38m
—segment totalsegment profit2022-01-01 → 2022-09-30¥1.5bn
Reconciling Itemsreconcilingrevenue2021-01-01 → 2021-09-30−¥35m
Reconciling Itemsreconcilingrevenue intersegment2021-01-01 → 2021-09-30−¥35m
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue2021-01-01 → 2021-09-30¥1.5bn
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue external2021-01-01 → 2021-09-30¥1.5bn
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue intersegment2021-01-01 → 2021-09-30¥35m
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentsegment profit2021-01-01 → 2021-09-30¥547m
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentrevenue2021-01-01 → 2021-09-30¥8.1bn
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentrevenue external2021-01-01 → 2021-09-30¥8.1bn
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentsegment profit2021-01-01 → 2021-09-30¥1.4bn
—segment totalrevenue2021-01-01 → 2021-09-30¥9.6bn
—segment totalrevenue external2021-01-01 → 2021-09-30¥9.5bn
—segment totalrevenue intersegment2021-01-01 → 2021-09-30¥35m
—segment totalsegment profit2021-01-01 → 2021-09-30¥2.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 716
ItemContextValueUnit
Profit loss before tax IFRSPrior1YTDDuration1568739000JPY
Profit loss before tax IFRSCurrentYTDDuration1223079000JPY
Depreciation expense ope cf IFRSPrior1YTDDuration274619000JPY
Depreciation expense ope cf IFRSCurrentYTDDuration388148000JPY
Decrease increase in trade and other receivables ope cf IFRSPrior1YTDDuration-113219000JPY
Decrease increase in trade and other receivables ope cf IFRSCurrentYTDDuration-940488000JPY
Increase decrease in trade and other payables ope cf IFRSPrior1YTDDuration-166079000JPY
Increase decrease in trade and other payables ope cf IFRSCurrentYTDDuration122325000JPY
Decrease increase in inventories ope cf IFRSPrior1YTDDuration-206453000JPY
Decrease increase in inventories ope cf IFRSCurrentYTDDuration-117673000JPY
Bonus allowance ope cf IFRSPrior1YTDDuration2227000JPY
Bonus allowance ope cf IFRSCurrentYTDDuration11549000JPY
Finance income and finance costs ope cf IFRSPrior1YTDDuration419976000JPY
Finance income and finance costs ope cf IFRSCurrentYTDDuration540127000JPY
Other changes in working capital ope cf IFRSPrior1YTDDuration-467523000JPY
Other changes in working capital ope cf IFRSCurrentYTDDuration-392645000JPY
Subtotal ope cf IFRSPrior1YTDDuration1312287000JPY
Subtotal ope cf IFRSCurrentYTDDuration834423000JPY
Interest received ope cf IFRSPrior1YTDDuration42003000JPY
Interest received ope cf IFRSCurrentYTDDuration40229000JPY
Interest paid ope cf IFRSPrior1YTDDuration-24047000JPY
Interest paid ope cf IFRSCurrentYTDDuration-9568000JPY
Income taxes refund paid ope cf IFRSPrior1YTDDuration-575122000JPY
Income taxes refund paid ope cf IFRSCurrentYTDDuration-1028013000JPY
Net cash provided by used in operating activities IFRSPrior1YTDDuration755120000JPY
Net cash provided by used in operating activities IFRSCurrentYTDDuration-162928000JPY
Net decrease increase in time deposits inv cf IFRSPrior1YTDDuration-842341000JPY
Net decrease increase in time deposits inv cf IFRSCurrentYTDDuration-1159200000JPY
Purchase of property plant and equipment inv cf IFRSPrior1YTDDuration-260731000JPY
Purchase of property plant and equipment inv cf IFRSCurrentYTDDuration-723140000JPY
Proceeds from sale of property plant and equipment inv cf IFRSPrior1YTDDuration373000JPY
Proceeds from sale of property plant and equipment inv cf IFRSCurrentYTDDuration－JPY
Purchase of intangible assets inv cf IFRSPrior1YTDDuration-205921000JPY
Purchase of intangible assets inv cf IFRSCurrentYTDDuration-441652000JPY
Purchase of investment securities inv cf IFRSPrior1YTDDuration-242166000JPY
Purchase of investment securities inv cf IFRSCurrentYTDDuration-589252000JPY
Proceeds from sale of investment securities inv cf IFRSPrior1YTDDuration668767000JPY
Proceeds from sale of investment securities inv cf IFRSCurrentYTDDuration－JPY
Increase of rent deposit inv cf IFRSPrior1YTDDuration-13984000JPY
Increase of rent deposit inv cf IFRSCurrentYTDDuration-266000JPY
Decrease of rent deposit inv cf IFRSPrior1YTDDuration30000JPY
Decrease of rent deposit inv cf IFRSCurrentYTDDuration449000JPY
Collection of loans receivable inv cf IFRSPrior1YTDDuration10179000JPY
Collection of loans receivable inv cf IFRSCurrentYTDDuration3557000JPY
Other inv cf IFRSPrior1YTDDuration1739000JPY
Other inv cf IFRSCurrentYTDDuration－JPY
Net cash provided by used in investing activities IFRSPrior1YTDDuration-884057000JPY
Net cash provided by used in investing activities IFRSCurrentYTDDuration-2909505000JPY
Net increase decrease in short term borrowings fin cf IFRSPrior1YTDDuration-368724000JPY
Net increase decrease in short term borrowings fin cf IFRSCurrentYTDDuration-200000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2021-12-31pass
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-01-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-07-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-01-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-01-01/2021-09-30pass
statement vs summary · revenueconsolidated 2021-07-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2021-12-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass